Zeymer, Uwe

Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation

Cannon, C. P., Bhatt, D. L., Oldgren, J., Lip, G. Y. H., Ellis, S. G., Kimura, T., Maeng, M., Merkely, B., Zeymer, U., Gropper, S., et al. (2017) · New England Journal of Medicine

Antiplatelet Therapy and Cardiovascular DiseasesAtrial Fibrillation Management and Outcomes

Cited by 1,383

PCI strategies in patients with acute myocardial infarction and cardiogenic shock

Thiele, H., Akin, I., Sandri, M., Fuernau, G., de Waha, S., Meyer-Saraei, R., Nordbeck, P., Geisler, T., Landmesser, U., Skurk, C., et al. (2017) · New England Journal of Medicine

Acute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

Cited by 1,209

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., Tromp, J., et al. (2022) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 951

Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review

Bauersachs, R., Zeymer, U., Brière, J.-B., Marre, C., Bowrin, K., & Huelsebeck, M. (2019) · Cardiovascular Therapeutics

Peripheral Artery Disease ManagementCardiovascular Health and Risk Factors

Cited by 449

β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease

Bangalore, S., Steg, G., Deedwania, P., Crowley, K., Eagle, K. A., Goto, S., Ohman, E. M., Cannon, C. P., Smith, S. C., Zeymer, U., et al. (2012) · JAMA

Acute Myocardial Infarction ResearchCardiac Health and Mental Health

Cited by 436

Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry

Suárez, C., Zeymer, U., Limbourg, T., Baumgartner, I., Cacoub, P., Poldermans, D., Röther, J., Bhatt, D. L., Steg, P. G., & REACH Registry Investigatorsa (2010) · Vascular Medicine

Peripheral Artery Disease ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 106

Screening for glucose perturbations and risk factor management in dysglycemic patients with coronary artery disease—a persistent challenge in need of substantial improvement: a report from ESC EORP EUROASPIRE V

Ferrannini, G., De Bacquer, D., De Backer, G., Kotseva, K., Mellbin, L., Wood, D., Rydén, L., collaborators, E. V., Gale, C. P., Beleslin, B., et al. (2020) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 75

Two-year Vascular Hospitalisation Rates and Associated Costs in Patients at Risk of Atherothrombosis in France and Germany: Highest Burden for Peripheral Arterial Disease

Smolderen, K. G., Wang, K., de Pouvourville, G., Brüggenjürgen, B., Röther, J., Zeymer, U., Parhofer, K. G., Steg, P. G., Bhatt, D. L., & Magnuson, E. A. (2012) · European Journal of Vascular and Endovascular Surgery

Peripheral Artery Disease ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 61